{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:52:17Z","timestamp":1792187537046,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.rdc.2020.04.001","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T22:40:12Z","timestamp":1591915212000},"page":"463-511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Risk of Malignancy in Spondyloarthritis"],"prefix":"10.1016","volume":"46","author":[{"given":"Paras","family":"Karmacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Shahukhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","article-title":"Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population","volume":"52","author":"Mercer","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"9255","key":"10.1016\/j.rdc.2020.04.001_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20141337","article-title":"Analysis of the intricate relationship between chronic inflammation and cancer","volume":"468","author":"Chai","year":"2015","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.rdc.2020.04.001_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","article-title":"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?","volume":"46","author":"Coates","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2020.04.001_bib5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.semarthrit.2018.05.009","article-title":"Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis","volume":"48","author":"Luo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2020.04.001_bib6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/kew214","article-title":"Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study","volume":"55","author":"Lange","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2020.04.001_bib7","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","article-title":"A\u00a0comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort","volume":"66","author":"Gross","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2020.04.001_bib8","first-page":"1047","article-title":"Risk of non-melanoma skin cancer in patients with psoriasis: An updated evidence from systematic review with meta-analysis","volume":"11","author":"Wang","year":"2020","journal-title":"J\u00a0Cancer"},{"issue":"2","key":"10.1016\/j.rdc.2020.04.001_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2230.1991.tb00314.x","article-title":"Psoriasis therapy and the risk of skin cancers","volume":"16","author":"Mali-Gerrits","year":"1991","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"10.1016\/j.rdc.2020.04.001_bib10","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C","article-title":"The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study","volume":"73","author":"Stern","year":"1994","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.rdc.2020.04.001_bib11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/jdv.12742","article-title":"Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink","volume":"29","author":"Edson-Heredia","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.rdc.2020.04.001_bib12","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s10067-016-3396-5","article-title":"Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study","volume":"35","author":"Wilton","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2020.04.001_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2020.04.001_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/RHU.0000000000000364","article-title":"Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis","volume":"22","author":"Hagberg","year":"2016","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.04.001_bib16","doi-asserted-by":"crossref","unstructured":"Ballegaard C, Hellgren K, Cordtz R, et\u00a0al. OP0005 incidence of overall and sitespecific cancers in tnf inhibitor treated patients with psoriatic arthritis: a population-based cohort study from 4 Nordic countries. Available at: https:\/\/ard.bmj.com\/content\/78\/Suppl_2\/67.3","DOI":"10.1136\/annrheumdis-2019-eular.1763"},{"key":"10.1016\/j.rdc.2020.04.001_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2020.04.001_bib18","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A\u00a0meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2020.04.001_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"41","author":"Carmona","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor \u03b1 inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2020.04.001_bib22","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/art.38339","article-title":"Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden","volume":"66","author":"Hellgren","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2020.04.001_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/fcp.12171","article-title":"Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database","volume":"30","author":"Saliba","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.rdc.2020.04.001_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.111054","article-title":"Prevalence of monoclonal gammopathy among patients with psoriatic arthritis","volume":"39","author":"Eder","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2020.04.001_bib26","doi-asserted-by":"crossref","first-page":"32063","DOI":"10.1038\/srep32063","article-title":"Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis","volume":"6","author":"Deng","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.rdc.2020.04.001_bib27","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s10067-018-4086-2","article-title":"Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set","volume":"37","author":"Walsh","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2020.04.001_bib28","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3892\/ol.2017.6368","article-title":"Ankylosing spondylitis and the risk of cancer","volume":"14","author":"Chang","year":"2017","journal-title":"Oncol Lett"},{"issue":"12","key":"10.1016\/j.rdc.2020.04.001_bib29","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/ard.2002.004721","article-title":"Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study","volume":"62","author":"Feltelius","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2020.04.001_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bjc.1987.35","article-title":"Long term mortality after a single treatment course with X-rays in patients treated for ankylosing spondylitis","volume":"55","author":"Darby","year":"1987","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.rdc.2020.04.001_bib32","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.rdc.2020.04.001_bib33","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1182\/blood-2011-04-347559","article-title":"Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study","volume":"118","author":"Lindqvist","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2020.04.001_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-5-59","article-title":"Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma","volume":"5","author":"Hemminki","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"issue":"2","key":"10.1016\/j.rdc.2020.04.001_bib37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.24287","article-title":"Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies","volume":"125","author":"Anderson","year":"2009","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2004.08.028","article-title":"Medical history and risk for lymphoma: results of a population-based case-control study in Germany","volume":"41","author":"Becker","year":"2005","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.rdc.2020.04.001_bib39","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/annonc\/mdu365","article-title":"Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study","volume":"25","author":"Fallah","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.rdc.2020.04.001_bib40","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/annonc\/mdu144","article-title":"Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype","volume":"25","author":"Fallah","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.rdc.2020.04.001_bib41","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/art.23267","article-title":"Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin\u2019s lymphoma","volume":"58","author":"Mellemkjaer","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2020.04.001_bib42","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdr333","article-title":"Autoimmune disease and subsequent digestive tract cancer by histology","volume":"23","author":"Hemminki","year":"2012","journal-title":"Ann Oncol"},{"issue":"10089","key":"10.1016\/j.rdc.2020.04.001_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.rdc.2020.04.001_bib44","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","article-title":"Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts","volume":"78","author":"Boel","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2020.04.001_bib46","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/annrheumdis-2015-208174","article-title":"Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study","volume":"75","author":"Molt\u00f3","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2020.04.001_bib47","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10067-017-3905-1","article-title":"Prevalence of comorbidities and evaluation of screening in Chinese patients with spondyloarthritis","volume":"37","author":"Jiang","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2020.04.001_bib48","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/key241","article-title":"Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register","volume":"58","author":"Fagerli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.23185","article-title":"Prevalence of malignancy in psoriatic arthritis","volume":"58","author":"Rohekar","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/03009742.2013.834961","article-title":"Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis","volume":"43","author":"van der Heijde","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib52","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1186\/s12885-017-3757-8","article-title":"Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials","volume":"17","author":"Veettil","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib53","first-page":"71","article-title":"Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR)","volume":"32","author":"Westhovens","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2020.04.001_bib54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jbspin.2017.08.003","article-title":"Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs","volume":"85","author":"Atzeni","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.rdc.2020.04.001_bib55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3899\/jrheum.150648","article-title":"Obesity is common in axial spondyloarthritis and is associated with poor clinical outcome","volume":"43","author":"Maas","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"28","key":"10.1016\/j.rdc.2020.04.001_bib56","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016400","article-title":"Obesity in psoriatic arthritis","volume":"98","author":"Queiro","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib57","first-page":"122","article-title":"Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data","volume":"25","author":"Kaine","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40880-019-0368-6","article-title":"Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?","volume":"39","author":"Feng","year":"2019","journal-title":"Cancer Commun"},{"issue":"Suppl 2","key":"10.1016\/j.rdc.2020.04.001_bib59","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/annrheumdis-2018-eular.4200","article-title":"OP0303 Systematic screening of comorbidities improves vaccination rates, skin cancer screening and vitamin d supplementation in patients with axial spondyloarthritis: results of the comedspa prospective, controlled, one year randomised trial","volume":"77","author":"Molt\u00f3","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2020.04.001_bib60","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/annrheumdis-2017-212395","article-title":"Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics","volume":"77","author":"Frisell","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2020.04.001_bib61","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3899\/jrheum.170520","article-title":"Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: a comparative study with the general population and data from the ASAS-COMOSPA Study","volume":"45","author":"Bautista-Molano","year":"2018","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11739-015-1270-0","article-title":"Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience","volume":"11","author":"Fant\u00f2","year":"2016","journal-title":"Intern Emerg Med"},{"issue":"9","key":"10.1016\/j.rdc.2020.04.001_bib63","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2005.047514","article-title":"Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study","volume":"65","author":"Askling","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2020.04.001_bib64","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.cgh.2013.11.007","article-title":"Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease","volume":"12","author":"Castro","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.rdc.2020.04.001_bib65","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ygyno.2012.07.100","article-title":"Effect of autoimmune diseases on risk and survival in female cancers","volume":"127","author":"Hemminki","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.rdc.2020.04.001_bib66","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1002\/ijc.29657","article-title":"Risk of cancer of unknown primary after hospitalization for autoimmune diseases","volume":"137","author":"Hemminki","year":"2015","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.rdc.2020.04.001_bib67","first-page":"2262","article-title":"Autoimmune disease and subsequent urological cancer","volume":"189","author":"Liu","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"12","key":"10.1016\/j.rdc.2020.04.001_bib68","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.3899\/jrheum.160542","article-title":"Incidence of malignancies in a cohort of psoriatic arthritis patients taking traditional disease modifying antirheumatic drug and tumor necrosis factor inhibitor therapy: an observational study","volume":"43","author":"Costa","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2020.04.001_bib69","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","article-title":"Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register","volume":"49","author":"Saad","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.rdc.2020.04.001_bib70","first-page":"672","article-title":"Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register","volume":"56","author":"Saad","year":"2017","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X20300508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X20300508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:18:02Z","timestamp":1760181482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X20300508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0889857X20300508"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2020.04.001","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Malignancy in Spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2020.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}